NY-PYRAMID-ANALYTICS
21.3.2023 16:26:47 CET | Business Wire | Press release
Pyramid Analytics (Pyramid), a leading business analytics and decision intelligence provider, announced today that it is showcasing its latest additions to its award-winning Decision Intelligence Platform—Tabulate, a powerful new business modeling module; and Solve, a decision modeling and optimization plug-in for Tabulate—at the Gartner Data & Analytics Summit in Orlando, Florida, and at SAPinsider Vegas 2023 in Las Vegas, Nevada. Launched in October 2022, Tabulate lets business users model business processes with data in a governed, web-based experience while Solve allows business users to easily build and deploy advanced prescriptive and optimization models to guide data-driven decision-making on live data.
Solving the last mile of analytics
In an independent research survey of data workers commissioned by Pyramid in 2022, over 50 percent of respondents who already use BI tools said they exported their analytical data to Excel 50 percent of the time or more to build business models to drive the last mile decision frameworks they need in their jobs. Pyramid added Tabulate and the Solve plug-in to address this “last mile” challenge and complete its “Data Factory for Decisions” paradigm: an end-to-end data fabric, analytics, and AI-driven assembly line that takes data from conception to decision point through a no-code, frictionless experience for business users.
Tabulate, a browser-based virtual spreadsheet that functionally matches desktop spreadsheet tools, allows business users to combine data from multiple data sources with their own business models and logic that reflects business processes that are not inherently captured in the data itself. The data is read live and directly from sources, without ingestion or duplication, vastly increasing time to insights while eliminating governance and security issues.
Solve, a plug-in for Tabulate, enables decision modeling by generating prescriptive and optimization models to drive real what-if analysis, simulations, and actual decision generation. The use cases are limitless, from supply-chain optimization to product price calculations and personnel scheduling.
Best of all, Tabulate and Solve, like all other elements in the Pyramid analytic catalog, can be deployed and consumed by other users on the Pyramid platform without ever having to take custody of the underlying models or spreadsheet content directly.
Key points:
- For years, there has been an elusive “Last Mile” of data analytics, which hinders business users from generating answers to the question: “How do we make it happen?” The launch of Tabulate and Solve means the Pyramid Platform has bridged that gap—supporting the data journey from creation to the end-user decision point.
- Tabulate is designed for business modeling by business users of all levels through a very familiar and comprehensive spreadsheet experience, complete with the 500+ functions found in other well-known spreadsheet tools.
- Tabulate enables business users to build and deploy business models using live data, no matter where it is.
- The Solve plug-in allows business users to build optimization models with complex logic waterfalls, conditions, and decision points. These can drive prescriptive analytics, optimization logic, what-if scenarios, and simulations.
- Tabulate and Solve are the latest innovation in Pyramid’s ongoing mission to enable business users to absorb data and enrich it with models and values, embellish it through logic, and gain insights through visualization and interrogation.
In the upcoming Pyramid 2023 release, users will be able to generate spreadsheet formulas in Tabulate using GPT-based natural language from the newly announced OpenAI integration.
Click here to schedule a demo of the Pyramid Decision Intelligence Platform.
Taking business intelligence to the next level
Today’s data-driven businesses are making faster, more accurate decisions based on facts rather than perception. But businesses need a platform that fully leverages all their data to become truly data-driven. Many organizations have discovered that their current business intelligence platforms are incomplete and not fit for purpose—focusing on data visualization rather than providing fast, accurate answers to actual business questions. This leaves them stuck in the past, making slow decisions, no decisions, or worse, bad decisions.
The Pyramid Decision Intelligence Platform changes that. It empowers people with AI augmentation, automation, and collaborative insights that simplify and guide the use of data in decision-making. It combines governed self-service analytics with AI and brings data prep, business analytics, and data science together into one frictionless platform.
Quotes:
Avi Perez, CTO and Co-Founder, Pyramid Analytics: “Tabulate and Solve are an exciting and mechanically crucial element in the data factory—a concept that has been part of the original Pyramid roadmap for over a decade. One of the most significant data challenges businesses face is the risks associated with moving data between standalone platforms or exporting to traditional spreadsheets stored on local machines. Tabulate removes the risks of this with governed direct connectivity, with data able to be utilized, deployed, and analyzed from any platform. Solve brings elusive prescriptive analytics to self-service ABI platforms. Both expansions help deliver true decision intelligence using real-time data.”
Omri Kohl, CEO and Co-Founder, Pyramid Analytics: “When we originally conceived the idea for the Pyramid platform, we set out to bring complex and sophisticated decision-making solutions to the general business user. Pyramid wants everyone, from CEOs to frontline workers, to gain valuable insights from data and make informed business decisions. The Tabulate and Solve expansion is the next step in the journey of making that dream a concrete reality. They combine sophistication, adaptability, functionality, and familiarity to create an easy-to-use, valuable tool for business users.”
About Pyramid Analytics
Pyramid Analytics is the next generation of decision intelligence. The award-winning Pyramid Decision Intelligence Platform empowers people with AI-augmented, automated, and collaborative insights that simplify and guide the use of data in decision-making. Critically, the Pyramid Platform operates directly on any data, enabling governed self-service for any person; and meeting analytical needs in a no-code environment without data extraction, ingestion, and duplication. It combines data prep, business analytics, and data science into one frictionless platform to empower anyone with intelligent decision-making. This enables a strategic, enterprise-wide approach to business intelligence and analytics, from the simple to the sophisticated. Schedule a demo today.
Pyramid Analytics is incorporated in Amsterdam and has regional headquarters in global innovation and business centers, including London, New York City, and Tel Aviv. Our team lives worldwide because geography should not hinder talent and opportunity. Investors include H.I.G. Growth Partners, Jerusalem Venture Partners (JVP), Sequoia Capital, and Viola Growth. Learn more at Pyramid Analytics.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230321005715/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
